bioRxiv · 10.1101/2020.05.27.118117
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
Abstract
COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no antiviral drugs or vaccines were developed against the closely related coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To identify starting points for such therapeutics, we performed a large-scale screen of electrophile and non-covalent fragments through a combined mass spectrometry and X-ray approach against the SARS-CoV-2 main protease, one of two cysteine viral proteases essential for viral replication. Our crystallographic screen identified 71 hits that span the entire active site, as well as 3 hits at the dimer interface. These structures reveal routes to rapidly develop more potent inhibitors through merging of covalent and non-covalent fragment hits; one series of low-reactivity, tractable covalent fragments was progressed to discover improved binders. These combined hits offer unprecedented structural and reactivity information for on-going structure-based drug design against SARS-CoV-2 main protease.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Douangamath, A., Fearon, D., Gehrtz, P., Krojer, T., Lukacik, P., Owen, C. D., Resnick, E., Strain-Damerell, C., aimon, A., Abranyi-Balogh, P., Brandao-Neto, J., Carberry, A., Davison, G., Dias, A., Downes, T. D., Dunnett, L., Fairhead, M., Firth, J. D., Jones, S. P., Keely, A., Keserü, G. M., Klein, H. F., Martin, M. P., Noble, M. E. M., O'Brien, P., Powell, A., Reddi, R., Skyner, R., Snee, M., Waring, M. J., Wild, C., London, N., von Delft, F., Walsh, M. A.. 2020-05-27. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. https://doi.org/10.1101/2020.05.27.118117
Cite the original work for its findings. Save a collection to share your selection of sources.